Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats
Joint Authors
Vareda, Priscilla Maria Ponce
Camaforte, Nathalia Aparecida de Paula
Violato, Natalia Moretti
Bosqueiro, José Roberto
Rafacho, Alex
Inácio, Maiara Destro
Teixeira, Poliana
Source
International Journal of Endocrinology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-11-08
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Objective.
Fibrates are used as lipid-lowering drugs and are well tolerated as cotreatments when glucose metabolism disturbances are also present.
Synthetic glucocorticoids (GCs) are diabetogenic drugs that cause dyslipidemia, dysglycemia, glucose intolerance, and insulin resistance when in excess.
Thus, we aimed to describe the potential of bezafibrate in preventing or attenuating the adverse effects of GCs on glucose and lipid homeostasis.
Methods.
Male Wistar rats were treated with high-dose bezafibrate (300 mg/kg, body mass (b.m.)) daily for 28 consecutive days.
In the last five days, the rats were also treated with dexamethasone (1 mg/kg, b.m.).
Results.
Dexamethasone treatment reduced the body mass gain and food intake, and bezafibrate treatment exerted no impact on these parameters.
GC treatment caused an augmentation in fasting and fed glycemia, plasma triacylglycerol and nonesterified fatty acids, and insulinemia, and bezafibrate treatment completely prevented the elevation in plasma triacylglycerol and attenuated all other parameters.
Insulin resistance and glucose intolerance induced by GC treatment were abolished and attenuated, respectively, by bezafibrate treatment.
Conclusion.
High-dose bezafibrate treatment prevents the increase in plasma triacylglycerol and the development of insulin resistance and attenuates glucose intolerance in rats caused by GC treatment, indicating the involvement of dyslipidemia in the GC-induced insulin resistance.
American Psychological Association (APA)
Inácio, Maiara Destro& Rafacho, Alex& Camaforte, Nathalia Aparecida de Paula& Teixeira, Poliana& Vareda, Priscilla Maria Ponce& Violato, Natalia Moretti…[et al.]. 2018. Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats. International Journal of Endocrinology،Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1171239
Modern Language Association (MLA)
Inácio, Maiara Destro…[et al.]. Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats. International Journal of Endocrinology No. 2018 (2018), pp.1-12.
https://search.emarefa.net/detail/BIM-1171239
American Medical Association (AMA)
Inácio, Maiara Destro& Rafacho, Alex& Camaforte, Nathalia Aparecida de Paula& Teixeira, Poliana& Vareda, Priscilla Maria Ponce& Violato, Natalia Moretti…[et al.]. Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats. International Journal of Endocrinology. 2018. Vol. 2018, no. 2018, pp.1-12.
https://search.emarefa.net/detail/BIM-1171239
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1171239